fbpx
The FibreGum study – Changing the course of obesity

The FibreGum study – Changing the course of obesity

The FibreGum study – Changing the course of obesity

The goal of our study is to increase weight reduction in obese children and adolescents by stimulating the gut microbiome with a chewing-gum containing dietary fibres as an adjunct treatment to standard adiposity therapy.

Around one in six children in Switzerland is affected by overweight or obesity and the prevalence continues to rise. This increase in obesity and its associated comorbidities represents a huge socio-economic burden, as it leads to increased morbidity and mortality. Obesity is not only a chronic disease in itself, but also a major risk factor for the development of the world’s leading causes of poor health and early death; namely cardiovascular disease, various cancers, diabetes and osteoarthritis.

Read more about the project here.

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

SDVF is part of the ADA Innovation Challenge expert panel 

SDVF is part of the ADA Innovation Challenge expert panel 

SDVF is part of the ADA Innovation Challenge expert panel 

The Swiss Diabetes Venture Fund (SDVF), which DCBs CEO Derek Brandt is general partner of, will be part of the expert panel of the Diabetes Innovation Challenge run by the American Diabetes Association (ADA). The Innovation Challenge will be part of the 83rd Scientific Sessions from June 23–26 in San Diego, CA.

For their Innovation Challenge, the ADA is welcoming emerging companies to pitch pioneering ideas in support of improving the lives of people living with diabetes. Five finalists will be selected to present in front of a live audience at the ADA’s Scientific Sessions in San Diego. 

 The three winning start-ups will be selected by the audience and the panel of expert judges from the Swiss Diabetes Venture Fund, The Helmsley Charitable Trust, and StartUp Health. Winners will earn an opportunity to attend a private event with the three judges and the Chief Scientific and Medical Officer of ADA, Dr. Robert Gabbay immediately following the presentation.  

Applications are open until 5 May. More information can be found here.

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Newsletter #5/23: DID YOU KNOW… what happens when blood glucose rises rapidly?

DCB Newsletter #5/23: DID YOU KNOW… what happens when blood glucose rises rapidly?

DCB Newsletter #5/23: DID YOU KNOW… what happens when blood glucose rises rapidly?

Dear Community,

We gladly present to you the next episode of our series “DID YOU KNOW” where we publish medical facts around diabetes that you might not know yet. Enjoy the read and thank you Dr. Stefanie Hofer for being our author again!  

We know that chronic high blood glucose can have serious long-term health consequences, but what happens when blood glucose rises extremely high in a short time? Hyperglycaemia can become an immediate, potentially fatal emergency. Here is what you need to know!

We divide hyperglycaemic emergencies into two forms: Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS). Their common element is an extremely high blood glucose level, and they differ in the presence of ketones. Ketones are an alternative source of energy for the body when it cannot use energy from sugar due to a lack of insulin. Both DKA and HHS usually occur in insulin-dependent people due to missed insulin injections, stress or infection. 

1. Diabetic Ketoacidosis: Keto – ketones, acidosis – acidification of the blood  

DKA is characterised by very high blood glucose levels, usually 350 – 600 mg/dl, and high levels of ketones in blood and urine. Common symptoms are heavy breathing, diarrhea, vomiting, confusion and possibly unconsciousnessDKA typically affects people with type 1 diabetes, where a complete lack of insulin leads to high ketone production. Because ketones are dangerous in large amounts, the body tries to get rid of its toxic compounds (acetone) by exhaling them via the lungs – resulting in a fruity breath reminiscent of nail polish remover or alcohol. This is why people with DKA are often mistaken for passed-out drunks at night. Without immediate medical treatment, DKA can lead to severe dehydration, loss of consciousness or death. 

2. Hyperosmolar Hyperglycaemic State   

Hyperosmolar means that there is too much sugar (and other molecules) in the blood and not enough water to dilute it. In HHS we see extremely high levels of glucose, usually over 1000 mg/dl (55 mmol/L), but no ketones. HHS develops slowly over several days and occurs typically in people with type 2 diabetes, often older people. The first symptoms are often extreme thirst and dehydration, frequent urination and nausea. Warning signs of progression include confusion, loss of vision and eventually unconsciousness or coma.   

Hyperglycemic Emergencies – Drunk or Diabetes?  

As the brain is dependent on glucose for function, the first symptom of any disruption in glucose metabolism is often confusion or some change in mental status. When medical students ask, “Which patient should we do a glucose test on in the emergency room?“ A common response is: “Any funny patient!“ – referring to signs of confusion or odd behaviour when glucose metabolism has gone out of balance.  

 
By looking out for these warning signs (confused, dehydrated, unconscious) in our environment, we can recognise hyperglycemic emergencies earlier and facilitate prompt, professional medical attention – and prevent dire consequences.  

Thanks so much for reading and we’ll provide you with the next episode of this series soon!

This post was previously published in Linkedin. Click here to see the original publication.

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Newsletter #4/23: INSIDE DCB – Interview with Prof. Lilian Witthauer 

DCB Newsletter #4/23: INSIDE DCB – Interview with Prof. Lilian Witthauer 

Dear Community, 

We’re thrilled to present you with the next episode or our series “INSIDE DCB” – this time, an interview with Prof. Lilian Witthauer. Enjoy the read!

Since 2021, Lilian Witthauer has been a professor specialising in sensor technology at the University Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) and at the DCB (Diabetes Center Berne). Together with her team, she researches innovative sensor technologies to improve the daily lives of people with diabetes.

Lilian, what is your research about?

My field of research is very interdisciplinary and includes both the scientific fundamentals of sensor technology and the clinical aspects of diabetes research. In particular, I focus on the development and improvement of sensors that enable people with diabetes to continuously measure blood glucose levels. An important aspect of my work is to make these sensors more accurate and reliable to enable automated insulin delivery. To achieve this goal, we redesign sensors, use different materials and optimise insulin delivery.

What motivates you to work in the field of diabetes technology? How did you get into it as a physicist?

What motivates me most is that people with diabetes can live better lives by having access to advanced sensor technologies that improve their healthcare and promote self-control and responsibility. I am involved in the field of diabetes technology as a physicist because I have always been interested in the application of physical principles and methods in medicine. As part of a changing society, diabetes is an important topic where there are still many opportunities for development.

What is your biggest challenge as a professor?

My biggest challenge as a professor is to find a balance between research, teaching and administration and to ensure that my team and I achieve our goals effectively and efficiently. This is not always easy, as I only have a short time for each individual task. It’s like I’m strategically managing a company, and at the same time I’m responsible for the operational implementation, while also taking care of the finances and IT.

Professor Dr. Lilian Witthauer. Assistant Professor with Tenure Track in Diabetes Technology. Photo credit: Sandra Blaser

What goals do you want to achieve with your team and your laboratory, the samlab (Sensing and Monitoring Lab)?

In collaboration with my team and samlab, I am pursuing the goal of developing innovative sensor technologies that make everyday life easier for people with diabetes and improve their quality of life. In addition, we want to promote interdisciplinarity and closely link our research results with practice.

What projects are you currently researching and how can they make life easier for people with diabetes?

One of my current projects deals with the development of a sensor that measures the glucose level in the blood continuously and without delay. The instantaneous measurement is of special interest when the blood glucose level changes rapidly, during meals, sports, or stress. The glucose sensor is based on a light-based measurement method and therefore differs from existing sensors on the market.

Such a sensor could be worn longer and would allow for completely automated insulin delivery. This would reduce the number of decisions a person with diabetes has to make every day and thus improve the quality of life.

How do you work with the DCB?

The DCB offers a unique environment where I work closely with project managers and experts from the hospital, statistics and business environment. We have regular meetings and interdisciplinary working groups to coordinate our work and drive the development of innovative solutions. In addition, the DCB connects me with industry partners and start-ups, which is very important in my research field.

Where do you hope your research field will be in  5-10 years? What is your vision?

My vision is that in 5-10 years, a wide range of innovative sensor technologies will be available to make the daily lives of people with diabetes easier and improve their healthcare.

I hope that our research will help to make monitoring blood glucose levels easier and more accurate, and that people with diabetes will be able to make better decisions about their diet, exercise and insulin therapy based on real-time data.

About Lilian Witthauer

Lilian Witthauer is Assistant Professor of Diabetes Technology at the University of Bern and the Diabetes Center Berne (DCB). She studied physics in Basel, completed a Master of Advanced Studies in medical physics at ETH Zurich and graduated with a PhD in nuclear and particle physics from the University of Basel in 2015. Lilian Witthauer has done postdoctoral research in the development of optical sensors for navigation during surgery at the Department of Biomedical Engineering at the University of Basel and on oxygen sensors at Massachusetts General Hospital and Harvard Medical School in Boston (USA).

More about samlab: https://samlab.org

This post was previously published in Linkedin. Click here to see the original publication.

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

Berne and Washington D.C. – Today, DCB announced a collaboration with T1D1 (Type 1 From Day 1), an app by teenager Drew Mendelow. After his diagnosis with type 1 diabetes in 2020, the now 16-year old designed and built a mobile app to simplify diabetes management from day one of diagnosis. DCB is going to support the project with know-how and financial resources to develop the documentation needed to submit the T1D1 APP for approval with the FDA (US) as well as the European Union under the Medical Device Regulations (MDR).

The app currently has over 45,0000 downloads primarily in the US. The approval is necessary to continue usage and to be able to offer an adequate app solution for more people with diabetes in the future, both in Europe and in the US.

“We from the DCB are excited to be able to help a teenager maintaining his solution on the market – a solution from a person living with diabetes for people with the same needs”, said Derek Brandt, CEO of the Diabetes Center Berne.

Drew Mendelow (Founder of T1D1) at the DCB Start-Up Night 2023

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland